Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2025)

CG Oncology (CGON) has disclosed Net Income towards Common Stockholders for 3 consecutive years, with -$41.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 29.74% year-over-year to -$41.3 million, compared with a TTM value of -$160.8 million through Dec 2025, down 82.7%, and an annual FY2025 reading of -$161.0 million, down 82.87% over the prior year.
  • Net Income towards Common Stockholders was -$41.3 million for Q4 2025 at CG Oncology, up from -$43.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$12.4 million in Q1 2023 and bottomed at -$43.7 million in Q3 2025.
  • Average Net Income towards Common Stockholders over 3 years is -$26.4 million, with a median of -$21.4 million recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders dropped 16.48% in 2024, then plummeted 119.12% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$22.5 million in 2023, then crashed by 41.39% to -$31.8 million in 2024, then dropped by 29.74% to -$41.3 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CGON at -$41.3 million in Q4 2025, -$43.7 million in Q3 2025, and -$41.4 million in Q2 2025.